Neutrophils can produce Neutrophil Extracellular Traps (NETs), which are web-like structures consisting of chromatin aimed to capture pathogens. NETs appear to play a role in several diseases including rheumatic autoimmune diseases. Although NET formation was originally described as a NADPH oxidase (NOX)-dependent pathway, it appears that there are also NOX-independent pathways of NET release. Currently, no tools are available that can discriminate between different NET-forming pathways.Johan van der Vlag, theme Renal disorders, and colleagues, developed a novel method that allows the discrimination of NETs generated through NOX-dependent or NOX-independent pathways. Using this novel NET assay they showed the presence of different types of NETs in the blood of patients with various diseases.
Furthermore, they showed that NOX-dependent and NOX-independent NETs differ in their endothelial cell stimulatory capacity. These results indicate heterogeneity in NET-forming pathways in vivo and highlight the need for disease-specific strategies to prevent NET-mediated pathology.Their findings were recently published in Annals of the Rheumatic Diseases, the highest ranking journal in the field of Rheumatology.
Related news items
A personal touch of Marlies Cornelissen31 October 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Marlies Cornelissen.read more
Collective cancer invasion forms an integrin-dependent radioresistant niche29 October 2019
Anna Häger and Peter Friedl, theme Cancer development and immune defense, identified a new niche of cancer cell survival and developed an integrin inhibition therapy to overcome resistance. They have published their results in JEM.read more
Algorithm to predict which cancer patients benefit from immunotherapy29 October 2019
Rik Lindeboom and Michiel Vermeulen, theme Cancer development and immune defense, have developed an algorithm that can predict which cancer patients are more likely to benefit from immunotherapy. This new technology’s potential is described in Nature Genetics.read more
X² Ambition Award for Sandra Heskamp28 October 2019
This award is intended for 'coming women’: young, ambitious women at a stage of their careers where they make important career choices. This prize is especially for women who show exemplary behaviour within the organization where they work, but also outside their organization.read more